MoonLake Immunotherapeutics price target raised to $41 from $28 at Barclays

Barclays analyst Leon Wang raised the firm’s price target on MoonLake Immunotherapeutics to $41 from $28 and keeps an Equal Weight rating on the shares. The firm said Moonlake highlighted MIRA results recently, with SLK demonstrated clear efficacy and in-line safety. Wang added that SLK looks ultimately approvable if these data are recapitulated in a phase 3 trial, which would justify a higher valuation.